Olema Pharmaceuticals, Inc. OLMA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $157.7M+26.6% | $124.52M+44.6% | $86.14M+4.7% | $82.27M+61.0% | ||
| $21M+18.4% | $17.74M-5.7% | $18.82M-23.8% | $24.71M+21.2% | ||
| $178.7M+25.6% | $142.26M+35.5% | $104.96M-1.9% | $106.99M+49.7% | ||
| -$178.7M-25.6% | -$142.26M-35.5% | -$104.96M+1.9% | -$106.99M-49.7% | ||
| $16.25M+27.1% | $12.78M+53.9% | $8.31M+277% | $2.2M+457% | ||
| -$162.45M-25.5% | -$129.47M-34.0% | -$96.66M+7.8% | -$104.79M-47.4% | ||
| -$1.87+11.0% | -$2.10+2.3% | -$2.15+17.9% | -$2.62-44.8% | ||
| -$178.21M-25.6% | -$141.87M-35.6% | -$104.58M+1.9% | -$106.63M-49.5% | ||
| -$178.7M-25.6% | -$142.26M-35.5% | -$104.96M+1.9% | -$106.99M-49.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Olema Pharmaceuticals, Inc. profitable?
- Olema Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $185.2M over the trailing twelve months.
- What is Olema Pharmaceuticals, Inc.'s earnings per share?
- Olema Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.03.
- Where does Olema Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Olema Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.